March 2014

MARCH 2014 YEAR
VOLUME I ISSUE 1
CASE MANAGEMENT CONNECTION
CENTRAL VIRGINIA CHAPTER OF
CASE MANAGEMENT SOCIETY OF AMERICA
PREMIER ISSUE
President’s Message
Last weekend, I woke up to a sunny day and a rather comfortable morning. I saw
birds on my yard and a cardinal on my deck. It’s a sign of spring indeed and what is
more appropriate than a cardinal to signal spring is in the air.
So to welcome spring, the CVC Board is bringing back our Chapter’s newsletter,
Case Management Connection. This quarterly newsletter will provide current
and upcoming information on Central Virginia Chapter and CMSA to enhance
communication; sharing of knowledge, and networking among those who are in our
mailing list. Thanks to Lee Banks for volunteering to spearhead this newsletter.
CENTRAL VIRGINIA CHAPTER’S LOGO
The cardinal, our state bird, is
Central Virginia Chapter of
CMSA’s new logo.
Cardinal also means
“of foremost importance;
paramount”.
IN THIS ISSUE:
PRESIDENT’S MESSAGE
COMMITTEE NEWS
EDUCATIONAL OFFERINGS
YOUR CVC BOARD
ARTICLES OF INTEREST
Change in DOT physicals
regulations
Voluntary Recall of Effexor ER
Zogenix Launches Zohydro® ER as
First-in-Class Long-Acting
Hydrocodone Product
I am also looking forward to our annual all day Spring Conference on Friday,
March 21, 2014 at Lewis Ginter Botanical Garden in Richmond. This year’s
conference theme is Innovation, Collaboration and Advocacy. The Boston
Scientific’s presentation on Bronchial Thermoplasty for Severe Asthma in Adults
was rescheduled due to the snow to April 23, 2014. Please see the ad for more
information.
These two presentations are just a few of the benefits of being a CMSA and CVC
member. CMSA and CVC provides continuing education to its members, more
important now that the Commonwealth of Virginia Board of Nursing has adopted
regulations related to continued competency requirements for renewal of RN and
LPN licenses beginning August 1, 2015.
As the leading case management organization, CMSA advocates for the
advancement of case management since 1990 by developing case management
adherence guidelines, evidence-based tools and resources, standards of practice,
transition of care, public policy and advocacy. CMSA and CVC would like to invite
you to join us and be an active member. Please do not hesitate to contact me or any
of the Board Members via our e-mails at our website www.cvccmsa.org for any
question or feedback.
See you at our conferences, please stop and say hello
YOURS TRULY,
RUDY D. REGALADO JR., RN, BSN, MHA, CCM
CENTRAL VIRGINIA CHAPTER of CMSA
Est. 12/05/1995
P.O. Box 4256
Glen Allen, VA 23060
www.cvccmsa.org
MARCH 2014
VOLUME I ISSUE 1
COMMITTEE NEWS
Program:
COMMITTEE NEWS
Membership:
CVC provides an ongoing opportunity to
network and meet peers to exchange ideas and
information; ask questions to members online
relating to resources and providers across
Virginia and the USA; meeting providers,
sponsors, and vendors and establishing
networking relationships with them that make
our care coordination easier. CMSA and CVC
would like to invite you to join us and be an
active member. There are numerous
opportunities to be involved nationally and
locally in Board membership, various
committees, speakers’ bureau, research,
advocacy, and projects. CMSA and CVC are
here because of your membership so please join
or renew. Contact Linda Bradley at
omarf16@comcast.net
How to sign up
Go to http://www.cmsa.org “Individual” tab on
the left upper screen. Go to “Membership” box
and click join “now” and follow prompts.
The Program Committee is a dynamic committee responsible for our
Chapter’s educational offerings from topic selection to sponsorships.
The Committee is excited with the response so far to the Spring
Conference and is expecting a great turnout again this year. Kudos to
Carole and the Education/Program Committee. Please contact Carole
Wallis at (804) 512-3894 for registration and more information on
CVC’s educational offering.
CVC sponsored presentations comes with continuing education hours,
food, and prizes for a minimum fee and mostly free for members and
just one of the benefits of being a CMSA and CVC member. CMSA
and CVC provides continuing education to its members, important
now that the Commonwealth of Virginia Board of Nursing has
adopted regulations related to continued competency requirements for
renewal of RN and LPN licenses beginning August 1, 2015.
Public Policy:
The Public Policy Committee, under the auspices of CMSA’s Board
of Director’s (BOD), has identified goals, objectives and
informational tools to help members become involved in
understanding the legislative process. The Committee will be
communicating key items that could affect our practice, to the Board
of Director’s. CMSA’s Public Policy Committee will attempt to keep
Chapters abreast of key legislative developments and will offer
suggestions for action. If you are interested in this committee, please
contact Betty Overbey at med-rehab@verizon.net
Nomination:
This committee is responsible for identifying potential candidates for
replacement and upcoming vacancies in the Board membership. Any
CMSA and CVC member can express interest in joining the board when
openings are announced on a yearly basis.
Upcoming Board vacancies for next fiscal year term are: Board of
Directors, and Treasurer.
If you have an interest serving in the CVC Board, please contact Rosa
Hopkins at rosa.hopkins@rah-pg.com
There are numerous opportunities to be involved with CMSA nationally and CVC locally.
Join CMSA and CVC at www.cmsa.org
“Act as if what you do makes a difference. It does.”
William James
VOLUME I ISSUE 1
MARCH 2014
• REGISTRATION
OPEN NOW FOR
CMSA
NATIONAL
CONFERENCE
AND EXPO
PRESENTING YOUR CVC
OFFICERS AND BOARD
MEMBERS FOR FY 2013-2014
Past President:
• JUNE 17 -20, 2014
Rosa Hopkins
rosa.hopkins@rah-pg.com
President:
Rudy Regalado
rrega1216@aol.com
President Elect: Linda Bradley
omarf16@comcast.net
Secretary:
Gail Lyddane
gail_lyddane@pmagroup.com
Treasurer:
Linda McKinley
linda.mckinley@genexservices.com
Board Members:
One Year:
 Carole Wallis
cwallis@onecallcm.com
 Liang Hui-Kho
nursekuo@gmail.com
 Lee Bank
lbank@vmlins.org
Two Year:
 Diana Boswell
dirn58@gmail.com
 Betty Overby
med.rehab@verizon.net
 Logan Ferguson
lferguson@aocortho.com
Three Year:
 Rebecca Webb
rwebb@restorerehab.biz)
 Paula Pugh
paula_talley-pugh@bshsi.org
• CLEVELAND
CONVENTION
CENTER
• CLEVELAND,
OHIO
EDUCATIONAL OFFERINGS
CVC CMSA invites you to
Boston Scientific’s
Bronchial Thermoplasty (BT):
A New Procedure for Severe Asthma in Adults
Presented by:
David Duhamel, MD, FCCP
Director, Pulmonary Special Procedures Unit
Virginia Hospital Center
Topics of Discussion:




Current challenges in asthma management
Bronchial Thermoplasty with the Alair® System
Recent clinical data
Patient selection and management for BT
April 23, 2014
6:30 PM - Dinner and Presentation
Hondos Restaurant, 4120 Cox Road, Glen Allen, VA
Please RSVP to Dawn Potts by Friday, April 21st to:
dawn.potts@bsci.com or 703.862.2099
IF YOU WOULD LIKE TO BECOME MORE INVOLVED WITH OUR ORGANIZATION PLEASE CONTACT ONE OF THE
BOARD MEMBERS WITH IDEAS OR TO SEE JUST HOW YOU CAN BECOME INVOLVED. THE BOARD IS ALWAYS OPEN
TO NEW IDEAS AND ASSISTANCE IN MAKING OUR ORGANIZATION BETTER FOR YOU.

International Association of Rehab Nurses
2014 Annual Conference
April 4, 2014, 8:00 a.m., The Place at Innsbrook, Glen Allen, VA
Call Barbara Harvey: 757-873-1119 x 203 for questions
MARCH 2014
VOLUME I ISSUE 1
CASE MANAGEMENT CONNECTION
An important change in the regulations
concerning DOT physicals is coming this year
March 7, 2014
The new rule states that after May 21,
Voluntary Recall of Effexor XR
2014, in order to issue a DOT medical
certificate, a medical professional must be
Pfizer Inc. issued a voluntary recall of single lots of Effexor XR (venlafaxine
HCl) 150mg extended release capsules (30 count bottle), Effexor XR 150mg
extended release capsules (90 count bottle), and Greenstone LLC-branded
Venlafaxine HCl 150mg extended release capsules. This action is being taken
because a pharmacist reported a bottle of Pfizer’s Effexor XR contained a
capsule of an antiarrhythmic medication, Tikosyn (Dofetilide) 0.25mg, in
addition to the Effexor XR capsules. Effexor XR is a selective serotoninnorepinephrine inhibitor (SNRI) antidepressant used in the treatment of
depression, anxiety, migraine prevention, and neuropathic pain. Although no
adverse events have been reported, should a patient take Tikosyn, where
contraindications and drug interactions have not been considered by the
prescribing physician, it could cause serious adverse health consequences for
the patient with the potential to be fatal.
either a doctor of medicine, doctor of
osteopathy, doctor of chiropractic,
physician assistant, advanced practice
nurse, or any other medical professional
authorized by the particular state's law to
perform physical examinations. In
addition, the individual must pass an
examination of the Federal Motor
Carrier Safety Administration (FMCSA)
to become certified. Once certified and
registered, a medical examiner must be
recertified every 10 years and must
complete periodic refresher training
every five years.
March 13, 2014
Zogenix Launches Zohydro® ER as First-in-Class Long-Acting Hydrocodone Product
Late last week, California-based Zogenix launched its recently approved Zohydro® ER into the U.S. market
despite ongoing criticism that the long-acting version of hydrocodone does not possess any notable abusedeterrent properties. Intended for use in the treatment of pain severe enough to require around-the-clock pain
relief and for which alternative therapy options have failed, Zohydro ER is the first long-acting hydrocodone
product to hit pharmacy shelves. Until the launch of Zohydro ER, hydrocodone was only available in the United
States in combination products with non-opioid constituents (e.g. acetaminophen, ibuprofen, chlorpheniramine,
etc.) and was classified as a Schedule III controlled substance; however, Zohydro ER is classified as a Schedule
II controlled substance due to its single-entity composition. Many patient safety advocacy groups are concerned
about the lack of abuse-deterrent properties of this drug, given the FDA’s recent unpredictable actions regarding
the approval of long-acting opioid pain relievers. Zogenix indicates that an abuse-deterrent formulation is
currently being developed and may be available within the next three years, pending FDA approval.
We are committed to publishing as fine a newsletter as possible and we thank everyone who has submitted information to be included in the newsletter. We
still need everyone's help to keep the information flowing so please continue to send in information of events and articles of interest to others in the case
management arena. We welcome your feedback to make our newsletter relevant to our members and supporters.
Case Management Connection
Editorial Board
Lee Banks – lbank@vmlins.org
Rudy Regalado – rrega1216@aol.com